# Spiral Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spiral-therapeutics

- Industry: Pharmaceuticals
- Headquarters: South San Francisco, US
- Website: www.spiraltx.com
- Total disclosed funding: $25M
- Latest round: Series A (Oct 18, 2022)
- Investors on record: 4

## About

Based in the US, Spiral Therapeutics, Inc. focuses on developing innovative drug delivery solutions for treating balance disorders and hearing loss, particularly targeting Ménière’s disease.Spiral Therapeutics, Inc. was founded in 2016 and is headquartered in South San Francisco, US. The company specializes in advanced drug delivery systems for inner ear disorders, primarily aiming at Ménière’s disease treatments. The CEO, Hugo Peris, leads the company which has raised a total of USD 10.90 mn through several funding rounds, including a recent Series A round on August 30, 2023, co-led by Catalio Capital Management, Humboldt Fund, and Savoir Capital. This latest funding round represents the total amount raised by the company to date, which showcases its focused efforts in the biotech sector.Spiral Therapeutics specializes in developing advanced drug delivery systems aimed at treating balance disorders and hearing loss, focusing on Ménière’s disease. Its flagship product, SPT-2101, is a sustained-release steroid formulation designed for precise delivery to the inner ear using the Minimally Invasive Cochlear System (MICS™). This innovative technology addresses the challenges of inner ear drug delivery, targeting patients suffering from Ménière’s disease, which affects over 600,000 individuals in the United States.Spiral Therapeutics generates revenue through clinical trials and potential partnerships with healthcare providers for their proprietary drug delivery systems. Their B2B business model engages with healthcare institutions and specialists who treat patients with hearing loss and balance disorders. Revenue is anticipated through agreements for SPT-2101 as it advances through clinical trials and regulatory approval, integrating into treatment plans and clinical practices.Looking forward, Spiral Therapeutics plans to expedite the development of its inner ear disorder treatments, particularly SPT-2101, leveraging the USD 10.90 mn raised in the recent Series A funding. The funding will support ongoing clinical trials and further development initiatives. The company is also exploring expansion into additional markets beyond the United States, aiming to address similar healthcare needs in global regions by 2025.

## Funding rounds

- Series A, Oct 18, 2022, $11M — Savoir Capital, Catalio Capital Management, Humboldt Fund
- Series A, May 6, 2019, $5.6M — Inveready Asset Management
- Series A, Dec 10, 2018, $8.5M — Savoir Capital, Catalio Capital Management

## Investors

- Savoir Capital — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A
- Inveready Asset Management (https://capitalatlas.ai/funds/inveready-asset-management) — Series A
- Humboldt Fund (https://capitalatlas.ai/funds/humboldt-fund) — Series A